Edition:
India

Biotest AG (BIOG_p.DE)

BIOG_p.DE on Xetra

22.55EUR
19 Jan 2018
Change (% chg)

€0.55 (+2.50%)
Prev Close
€22.00
Open
€22.05
Day's High
€22.65
Day's Low
€21.80
Volume
27,694
Avg. Vol
29,839
52-wk High
€23.88
52-wk Low
€13.88

Latest Key Developments (Source: Significant Developments)

Biotest: All Conditions Met For Creat Takeover Of Biotest
Friday, 19 Jan 2018 

Jan 19 (Reuters) - BIOTEST AG ::DGAP-ADHOC: BIOTEST AG: ALL CONDITIONS MET FOR CREAT TAKEOVER OF BIOTEST.FOREIGN TRADE APPROVAL HAS BEEN GIVEN BY U.S. COMMITTEE ON FOREIGN INVESTMENT IN UNITED STATES (CFIUS).LAST REMAINING CONDITION HAS BEEN MET FOR TAKEOVER OFFER BY TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG.THUS UNSOLICITED TAKEOVER BID ANNOUNCED ON MAY 18, 2017 FOR SHARES OF BIOTEST AG BECOMES EFFECTIVE.IN CONNECTION WITH APPROVAL, BIOTEST HAS SIGNED AN AGREEMENT FOR SALE OF ITS U.S. COMPANIES.  Full Article

Biotest 9-mth revenue at EUR 377.8 mln
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - BIOTEST AG ::DGAP-NEWS: BIOTEST AG: BIOTEST GENERATES REVENUES OF EUR 377.8 MILLION IN THE FIRST NINE MONTHS 2017.9M REVENUE 377.8 MILLION EUR.‍PAUL-EHRLICH INSTITUTE APPROVES PHASE III TRIAL IN INDICATION OF ACQUIRED FIBRINOGEN DEFICIENCY​.‍EBIT OF CONTINUING OPERATIONS TOTALED EUR -15.7 MILLION IN FIRST THREE QUARTERS OF 2017 AFTER EUR 47.5 MILLION​.9-MONTH ‍EARNINGS AFTER TAXES OF CONTINUING OPERATIONS OF EUR -22.7 MILLION VERSUS EUR 13.3 MILLION YEAR AGO​.  Full Article

Biotest: Tiancheng withdrawal of application of transaction from CFIUS and refiling
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - BIOTEST AG ::‍TENDER OFFER BY TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG​.‍TIANCHENG WITHDRAWAL OF APPLICATION OF TRANSACTION FROM CFIUS AND REFILING​.BIOTEST - ‍TIANCHENG AND BIOTEST TO WITHDRAW THEIR NOTICE AND TO REFILE NEW APPLICATION WITH REQUEST FOR EXPEDITED REVIEW PERIOD​.  Full Article

Biotest opens new plasma collection centre in Vermillion, USA
Wednesday, 28 Sep 2016 

Biotest AG :Biotest opens new plasma collection centre in Vermillion, South Dakota, USA.  Full Article

Biotest H1 result after tax swings to profit of EUR 7.7 mln
Thursday, 11 Aug 2016 

Biotest AG : H1 revenue rose 6.4 percent to 306.1 million euros ($341.18 million) . H1 EBIT increased considerably from 2.3 million euros to 18.2 million euros . H1 pretax profit 13.9 million euros . H1 profit after tax 7.7 million euros versus -2.2 million euros loss year ago .Board of management confirms guidance of an increase in sales in low single-digit percentage range and an EBIT in range of 33 million to 35 million euros for 2016.  Full Article

Biotest: altered tax assessments for 2005 - 2008
Wednesday, 3 Aug 2016 

Biotest AG : Altered tax assessments for 2005 - 2008 . Tax Office Offenbach am Main served to Biotest AG altered tax assessments for corporate tax, solidarity tax and trade tax for years 2005 until 2008 . Alterations are based on investigations by tax authorities and public prosecutor in connection with Russia business of Biotest AG . This leads to liabilities for tax and interest totalling to approx. 20 million euros ($22.34 million) . Company will have tax assessments evaluated by their tax consultants .According to our first appraisal this approach by financial authorities is conflicting with recently published decisions by Federal Fiscal Court on tax deduction of operating expenses.  Full Article

Biotest opens fifth plasma collection centre in Hungary
Friday, 29 Jul 2016 

Biotest AG :Opens fifth plasma collection centre in Hungary.  Full Article

Biotest opens new plasma collection centre in U.S.
Wednesday, 27 Jul 2016 

Biotest AG :Opens new plasma collection centre in Clemson, South Carolina, USA.  Full Article

Biotest opens new plasma collection centre in USA
Tuesday, 24 May 2016 

Biotest AG :Opens new plasma collection centre in Brookings, South Dakota, USA.  Full Article

Biotest: Pentaglobin shows significant survival benefit in severe infections caused by multidrug resistant bacteria
Monday, 23 May 2016 

Biotest AG : Pentaglobin(r) showed a significant survival benefit in severe infections caused by multidrug resistant bacteria . Additional therapy with Pentaglobin significantly reduced relative mortality risk by 33% in patients with confirmed resistance to antibiotics .Greatest relative survival benefit of 39% was seen in subgroup with infections by extensively drug resistant(XDR) bacteria.  Full Article

Biotest sheds U.S. business to allay U.S. concerns of Chinese takeover

FRANKFURT Biotest said on Friday that it has sold its U.S. operations, allaying national security concerns by U.S. authorities and paving the way for the German company's sale to a Chinese investor.